The Cochrane Haematological Malignancies Group (CHMG) is one of 52 Cochrane Review Groups of Cochrane.

The goal of this global independent network of researchers, professionals, medical doctors, patients and people interested in health is the production, updating and dissemination of high-quality Cochrane Reviews on the effects of interventions for patients with haematological malignancies. 

The CHMG was formed in 2000 by Prof. Andreas Engert and is situated at the Department I of Internal Medicine of the University Hospital of Cologne, Germany. Since January 2014, Dr. Nicole Skoetz is leading the group as co-ordinating editor. Besides of the team in Cologne, the CHMG has an international network of editors worldwide, such as from Australia, Brasil, Germany, Denmark, Great Britain, Switzerland, and the United States who work together for improving quality of the Cochrane Reviews. In cooperation with other authors and patients from more than 20 other countries they build an active network for healt-care information.

The CHMG's main area of focus are adult patients with haematological malignancies, such as leukaemias and lymphomas, but also non-oncological haematological diseases such as aplastic anaemia. We also focus on Cochrane Reviews about supportive care, stem cell transplantation and haematological growth factors.

The main roles of the CHMG are

• the development and publication of Cochrane Reviews within the main research area in the Cochrane Library
• the development of a register of randomised controlled clinical trials
• the knowledge transfer to medical doctors, patients, professionals and interested people

The CHMG follows the rules of Cochrane.